Support teaching, research, and patient care.
We seek to understand the mechanisms responsible for the resistance of solid tumors to cancer therapies and to develop strategies to overcome these resistances. The main project is We are investigating the role of bone marrow derived cells in restoring the tumor vasculature after radiotherapy (which destroys local angiogenesis). This process is known as vasculogenesis. In particular we seek to improve tumor cure rates by radiotherapy by inhibiting the repair of the tumor vasculature in GBM by circulating cells following radiation to the tumors by selective inhibition of the chemokine pathway(s) responsive for the mobilization and capture in the tumor of the circulating proangiogenic cells.
Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma
This phase II trial studies how well whole brain radiation therapy works with standard
temozolomide chemo-radiotherapy and plerixafor in treating patients with glioblastoma (brain
tumor). Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors.
Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth
of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping
them from spreading. Plerixafor is a drug that may prevent recurrence of glioblastoma after
radiation treatment. Giving whole brain radiation therapy with standard temozolomide
chemo-radiotherapy and plerixafor may work better in treating patients with glioblastoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Lawrence Recht, 650-725-8630.
View full details